comparemela.com

Latest Breaking News On - Mantle cell lymphoma - Page 3 : comparemela.com

Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Ibrutinib-combined-with-venetoclax
Patients-with
Refractory-mantle-cell-lymphoma
Primary-analysis-results-from
Randomized-phase
Ibrutinib
Venetoclax
Cmcl
Mantle-cell-lymphoma
Rr-mcl
Relapsed-refractory-mantle-cell-lymphoma

Future Directions and Unmet Needs in Relapsed/Refractory MCL

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Recent-updates
Follicular-lymphoma
Mantle-cell-lymphoma
Unmet-needs
Cmcl
Relapsed-refractory-mcl
Relapsed-refractory-mantle-cell-lymphoma
Triangle-trial
Shine-trial
Sympatico-trial
Dbtk

Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

California
United-states
University-of-california-irvine
Catherinec-coombs
Niravn-shah
Swetha-kambhampati
Department-of-medicine
College-of-wisconsin
Division-of-hematology
School-of-medicine
California-irvine
Onclive-institutional-perspectives

Dr Cohen on Available Treatments For MCL

Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.

Jonathonb-cohen
Winship-cancer-institute
Lymphoma-program
Emory-university-school-of-medicine
Safety-monitoring-committee
Department-of-hematology
Medical-oncology
Emory-university-school
Winship-cancer-institute-of-emory-university
Mantle-cell-lymphoma
Onclive-tv

Mitigating Financial Toxicity in Cancer Care Requires Policy Reform, Rethinking Benefit Design

From the panel discussion, "The Burden They Carry," a discussion of the impact of financial toxicity over the duration of the cancer journey.

Minnesota
United-states
Tennessee
New-jersey
Vanderbilt-university
Cinnaminson
American
Anita-kumar
Stacieb-dusetzina
Rajini-katipamula-malisetti
Brian-osullivan
Vanderbilt-university-medical-center

vimarsana © 2020. All Rights Reserved.